Choreo LLC Buys 5,664 Shares of Pfizer Inc. $PFE

Choreo LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 181,463 shares of the biopharmaceutical company’s stock after purchasing an additional 5,664 shares during the quarter. Choreo LLC’s holdings in Pfizer were worth $4,399,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Amundi raised its stake in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new stake in shares of Pfizer in the 1st quarter worth approximately $389,861,000. Vanguard Group Inc. increased its position in Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Goldman Sachs Group Inc. increased its position in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after purchasing an additional 9,041,990 shares during the period. Finally, Northern Trust Corp raised its holdings in Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on PFE shares. Scotiabank began coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Morgan Stanley reduced their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Finally, Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Stock Down 0.0%

PFE stock opened at $25.72 on Thursday. The business has a 50 day moving average of $24.94 and a 200 day moving average of $24.55. The firm has a market cap of $146.21 billion, a PE ratio of 13.68, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.